학술논문
Ibrutinib in Refractory or Relapsing Primary Central Nervous System Lymphoma: A Systematic Review.
Document Type
Article
Author
Nepal, Gaurav; Khurana, Mahika; Bucheli, Domenica Herrera; Bhandari, Siddhartha; Joshi, Utsav; Bhagat, Riwaj; Rehrig, Jessica Holly; Pudasainee, Prasun; Shing, Yow Ka; Ortiz, Juan Fernando; Ojha, Rajeev; Gajurel, Bikram Prasad; Quinonez, Jonathan; Ruxmohan, Samir; Albert, Trevine; Licata, Steven; Stien, Joel
Source
Subject
*CENTRAL nervous system
*BRUTON tyrosine kinase
*LYMPHOMAS
*NON-Hodgkin's lymphoma
*SPINAL cord
*
*
*
*
Language
ISSN
2035-8377
Abstract
Primary Central Nervous System Lymphoma (PCNSL) is a rare variant of Non-Hodgkin Lymphoma (NHL) representing 1–2% of all NHL cases. PCNSL is defined as a lymphoma that occurs in the brain, spinal cord, leptomeninges, or eyes. Efforts to treat PCNSL by traditional chemotherapy and radiotherapy have generally been unsuccessful as a significant proportion of patients have frequent relapses or are refractory to treatment. The prognosis of patients with Refractory or Relapsed (R/R) PCNSL is abysmal. The optimal treatment for R/R PCNSL is poorly defined as there are only a limited number of studies in this setting. Several studies have recently shown that ibrutinib, a Bruton tyrosine kinase (BTK) inhibitor, has promising results in the treatment of R/R PCNSL. However, these are preliminary studies with a limited sample size. In this systematic review, we explored and critically appraised the evidence about the efficacy of the novel agent ibrutinib in treating R/R PCNSL. [ABSTRACT FROM AUTHOR]